“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts. ”


Pavel Khrimian, Co-founder & CBO at Deka Biosciences Inc

Dr John Mumm and Pavel Khrimian co-founded Deka in Jan 2019. They have developed candidate molecules for the treatment of life-threatening diseases using targeted cytokine delivery platform Diakinecoupled with a precision medicine strategy. Their current focus is on oncology and inflammatory diseases such as Crohn’s, sepsis, and psoriasis. This narrative is the result of the June 10th, 2020 interview with Pavel Khrimian. The content has been edited for clarity.

Why was it important to evaluate the current commercial drugs during Diakine® development?

The commercial drugs provide a very good reference point for novel molecule development. They are often used as comparators in drug development.

What were your challenges before finding Evidentic?

The use of biosimilars was just not good enough for our target audience, who wanted to see in-vivo data of our novel Diakine™ compared to a commercial therapeutic drug.  We are very fortunate that we found Evidentic, as there were no other sources of therapeutic drugs that were readily available.

How did Evidentic help you?

We were able to effectively eliminate the questions by using the drug aliquots of therapeutic drugs from Evidentic to show the superiority of our Diakine™ in a mouse model.  Evidentic provides quality products with exceptional customer service, which enables an early-stage startup such as Deka Biosciences to succeed.

How did Evidentic services help your development process?

Thanks to Evidentic we were able to generate data that further validated our technology and the novelty behind our Diakines, as compared to standard of care.  Our goal is to change the standard of care for chronic diseases and the data generated [using drug aliquots] allowed us to make progress towards this goal.  The data was also critical from an IP perspective, data will feed into the patent application and will be used as a part of the IND package.

How was your overall experience with Evidentic?

Deka has worked with lots of suppliers and believe me when I say that Evidentic has the right culture and approach to clients. Evidentic shows care and appreciation for not only their own products, which is evident in the quality of your products, but you also care about your client’s research goals.  This is unique and it is much appreciated. I used to be in the supply chain for many years, so I know suppliers and supplier relationship management, you guys have been wonderful. The excellent communication (over weekends, over the phone, etc.) and customer service separate Evidentic from a lot of other suppliers.